Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy

NCT04779957 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplantation
Graft Failure

Interventions

DRUG: Tocilizumab

Sponsor

University Hospital, Toulouse